Application of the 1998 Pediatric Rule to Oncology Steven Hirschfeld, MD PhD CDR U.S. Public Health Service Medical Officer Division of Oncology Drug Products.

Slides:

Advertisements

Similar presentations

Common/shared responsibilities between jobs.

Advertisements

Single-Patient Use of Investigational Drugs and Biologic Products for Treating Cancer Grant Williams, M.D. Medical Team Leader DODP/CDER/FDA.

"Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.

Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.

Daniel J. Isaacman, m.D., FAAP

Regulatory Requirements for Orphan Drugs Delivery Dr. Basavaraj K. Nanjwade M.Pharm., Ph.D Professor of Pharmaceutics KLE University, Belgaum, India

© 2005 by Nelson, a division of Thomson Canada Limited. 1 Consumer Stakeholders: Product and Service Issues Search the Web The American Society for Quality.

UNITED SPINAL ASSOCIATION AUGUST, 2014 Biologics & Biosimilars: An Overview 1.

Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

Special Topics in IND Regulation

Current standards, donor safety, and blood supply

Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.

Oncology Pediatric Initiatives Richard Pazdur, MD Director, Division of Oncology Drug Products.

Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,

Business and Society: Ethics and Stakeholder Management, 5E Carroll & Buchholtz Copyright ©2003 by South-Western, a division of Thomson Learning. All.

1 One Year Post-Exclusivity Adverse Event Review: Ertapenem Pediatric Advisory Committee Meeting November 16, 2006 Alan M. Shapiro, MD, PhD, FAAP Medical.

Food and Drug Administration Center for Biologics Evaluation and Research The Office of Cellular, Tissue and Gene Therapies Web Seminar Series presents:

1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development IND Case Studies.

Screening Implementation: Referral and Follow-up What Do You Do When the Screening Test Is of Concern? Paul H. Lipkin, MD D-PIP Training Workshop June.

Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.

1 One Year Post Exclusivity Adverse Event Review: Ofloxacin Ophthalmic Pediatric Advisory Committee Meeting September 15, 2004 Hari Cheryl Sachs, MD, FAAP.

ORO Reviews: Frequent Findings Related to IRBs Bob Brooks Associate Director Research Compliance Education and Policy VHA Office of Research Oversight.

1 Kepivance™ (Palifermin) Basis for Approval and Pediatric Studies Kepivance™ (Amgen) Approved 12/15/04 Joseph E. Gootenberg, M.D. Office of Oncology Drug.

PATRICIA KERBY, MPA HUMAN SUBJECTIONS PROTECTION COMPLIANCE OFFICER OFFICE OF RESEARCH COMPLIANCE What are the FDA’s expectations in 2010?

1 Update to Post Exclusivity Pediatric Adverse Event Review: Simvastatin Pediatric Advisory Committee Meeting November 16, 2006 Jean Temeck, MD, Acting.

Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.

Public Health Issues Associated with Biological and Chemical Terrorism Scott Lillibridge, MD Director Bioterrorism Preparedness and Response Activity National.

FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.

1 Statistics in Drug Development Mark Rothmann, Ph. D.* Division of Biometrics I Food and Drug Administration * The views expressed here are those of the.

Overview of FDA's Regulatory Framework for PET Drugs

1 One Year Post Exclusivity Adverse Event Review: Carboplatin Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

1 One Year Post-Exclusivity Adverse Event Review: Meloxicam Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

History of Pediatric Labeling

Zometa for Patients with Bone Metastases Overview and Review of Study 010 Grant Williams, M.D. Medical Team Leader Division of Oncology Drug Products.

1 Ethical Concerns in Pediatric Placebo-controlled Trials from the European Experience Ethics of Placebo-controlled Trials in Children FDA Pediatric Advisory.

FDAAA – Report on DTC Advertising Kristin Davis, J.D. Deputy Director, Division of Drug Marketing, Advertising, and Communications Office of Medical Policy,

Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.

FDA Science Board CDER Drug Safety Update November 6, 2005 Rockville, MD Steven Galson, MD, MPH Director, Center for Drug Evaluation and Research Food.

Food and Drug Administration Amendments Act of 2007 Reauthorization of Pediatric Initiatives Lisa L. Mathis, M.D. Pediatric and Maternal Health Staff Office.

Agency for Healthcare Research and Quality Advancing Excellence in Health Care The “Centers for Education & Research on Therapeutics” (CERTs)

February 2, 2004 Pediatric Drug Development: A Decade of Progress: Susan K. Cummins, MD, MPH Medical Team Leader Division of Pediatric Drug Development.

General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,

The Regulatory Science of Regenerative Medicine Celia M. Witten, Ph.D., M.D., Director Office of Cellular, Tissue and Gene Therapies Center for Biologics.

1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.

CLIA Waiver for the OraQuick ® Rapid HIV-1 Antibody Test Elliot P. Cowan, Ph.D. Senior Regulatory Scientist Office of Blood Research and Review Center.

Opiate Analgesic Use in Pediatric Patients Bob Rappaport, M.D. Deputy Division Director Division of Anesthetic, Critical Care and Addiction Drug Products,

1 One Year Post Exclusivity Adverse Event Review: Ciprofloxacin Pediatric Subcommittee of the Anti-infective Drugs Advisory Committee Meeting June 9, 2004.

Initiatives Drive Pediatric Drug Development January 30, 2002.

1 Scaling-up ARV Therapy in Vietnam HAIVN Harvard Medical School AIDS Initiative in Vietnam.

1 Impediments to Early Initiation of Pediatric Studies in a Clinical Oncology Drug Development Program A Large Pharmaceutical Company Perspective  Corporate.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.

1 Update to Post-Exclusivity Pediatric Adverse Event Review: Oxybutynin Pediatric Advisory Committee Meeting November 16, 2006 Lisa Mathis, MD, Associate.

Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee July 15, 2003 Steven Hirschfeld, MD PhD CAPT USPHS Division of Oncology Drug.

Overview of Pediatric Drug Development Dianne Murphy, MD Director Office of Counterterrorism and Pediatric Drug Development Center for Drug Evaluation.

ROAD MAP: Getting a Cancer Study Done at Jefferson Sylvia O’Neill, MD Associate Director of Regulatory Affairs and Quality Assurance Clinical Trials Office.

1 One Year Post Exclusivity Adverse Event Review: Glimepiride Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.

1 BETTER APPROACHES TO MONITORING MEDICAL PRODUCT SAFETY ARE NEEDED.

Joint Non-Prescription Drugs and Pediatric Advisory Committee Meeting October 18-19, 2007 Considerations for Extrapolation of Efficacy from Adults to Children.

Dr. Dianne Murphy, M.D. Associate Director of Pediatrics September 12, 2000 Center for Drug Evaluation and Research Food and Drug Administration.

ROAD MAP: Getting a Cancer Study Done at Jefferson Meghan Wakefield,RN,CCRP Senior Director of Clinical Trials Office Clinical Research Organization.

Pediatric Drug Development: A Regulatory Perspective Tiffany R. Farchione, M.D. Medical Officer, Division of Psychiatry Products US Food and Drug Administration.

Recent Evolution of New Drug Review and Approval System in Korea

Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.

Suzanne M. Sensabaugh, MS, MBA

Lessons Learned from the Mistakes of Others

Pediatric Clinical investigator training workshop

Pediatric Therapeutics Still working to get it right for kids

Pediatric Drug Development A Regulatory Perspective

Presentation transcript:

Application of the 1998 Pediatric Rule to Oncology Steven Hirschfeld, MD PhD CDR U.S. Public Health Service Medical Officer Division of Oncology Drug Products Center for Drug Evaluation and Research Food and Drug Administration

Brief History n Pediatric therapeutic development has never been as thorough or robust as adult therapeutic development n Many therapies are administered to children without adequate study n Many therapies are not made available for pediatric study until after adult marketing studies are completed

Pathways to Development Conventional n Pre-clinical ---> Adult > Pediatric Possible n Pre-clinical ---> Adult + Pediatric n Pre-clinical ---> Pediatric - - -> Adult

FDA Pediatric Initiatives n 1994 Rule established principle of extrapolation of efficacy data from adult population to pediatric population if certain conditions were met n 1997 Exclusivity Extension in FDAMA

1998 Pediatric Rule n Mandates pediatric studies if the indication for an application under review can be found in children n Applies to drugs and biologicals n If the indication does not apply to children, then a waiver can be granted n Does not specifically address extrapolation of efficacy- raises issue of “Are studies warranted?” n Does not delay development for adult indication

Question for committee How should the 1998 Rule be applied for solid tumors and central nervous system malignancies?

Goals n Recommendations for adult indications that should trigger the Pediatric Rule n Recommendations for adult indications that should be waived from compliance n Recommendations for general principles that may used to apply the Pediatric Rule

Example of a principle n If a lesion is necessary for establishing or maintaining the malignant phenotype and if a therapy is directed against that lesion, then studies in tumors where the lesion occurs and has the same critical role are warranted